- Home
- UPST vs BLTE Comparison
UPST vs BLTE Comparison
Compare UPST & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UPST | BLTE |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.1B |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | UPST | BLTE |
|---|---|---|
| Price | $37.75 | $183.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | $59.96 | ★ $161.57 |
| AVG Volume (30 Days) | ★ 3.4M | 258.4K |
| Earning Date | 02-10-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $997,748,000.00 | N/A |
| Revenue This Year | $56.14 | N/A |
| Revenue Next Year | $23.75 | N/A |
| P/E Ratio | $150.40 | ★ N/A |
| Revenue Growth | ★ 64.93 | N/A |
| 52 Week Low | $31.40 | $49.00 |
| 52 Week High | $96.43 | $200.00 |
Technical Indicators
Market Signals| Indicator | UPST | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 31.08 | 70.14 |
| Support Level | $38.92 | $160.00 |
| Resistance Level | $46.09 | $200.00 |
| Average True Range (ATR) | 2.02 | 9.98 |
| MACD | -0.98 | 1.87 |
| Stochastic Oscillator | 8.19 | 67.73 |
Price Performance
Historical ComparisonAbout UPST Upstart Holdings Inc.
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit, and small-dollar loans.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.